TS-004619 — A medical device to assess tissue stiffness in the brain, particularly in epileptogenic brain tissue.

TS-004616 — A method for targeted delivery and constitutive expression of large genes using adeno-associated viral (AAVs) vectors that contain ubiquitous mini-promoters. Incorporation of the compact mini-promoters will increase the cargo space of the AAVs such that larger genes can be packaged into the vectors.

TS-004611 — This software tool annotates burns in existing medical records to accurately estimate %TBSA-burned and minimize errors from inaccurate annotations or miscalcualtions. This is acheived through mapping 2D images onto a body-accurate 3D geometry.

TS-004603 — In the case of mass casualty events, unidentified patients will be given an AirTag, which will track the patient’s location and allow the tracker to receive identifying patient details upon arrival to the hospital.

TS-004601 — A medical device used to detect a leak in an ostomy pouch and alert the user of the leak. This device would be implantable/ attached to the ostomy pouch and detect leaks via the presence of oxygen. Upon detection of the leak, the device would emit an alarm, or notify the user through their mobile phone such that they can replace the pouch in a timely manner.

TS-004565 — A method for proteolytic inactivation of respiratory syncytial virus (RSV) with bacterial proteases purified from oral bacteria Porphyromonas gingivalis. Thus, a potential new antiviral for treatment of severe RSV infection.

TS-003679 — The IP is an innovative approach to the preoperative treatment of severe spinal deformities, particularly in medically complex children. Traditionally, halo gravity traction (HGT) has been employed as a preoperative tool, involving hospital admission for the duration of treatment. However, for certain patients, especially those who are too young or medically complex, spinal surgery with instrumentation presents significant risks and challenges. The program offers two innovative pathways: Long-Term HGT: For patients deemed unsuitable candidates for immediate surgery due to medical complexity or unique deformities, a long-term halo gravity traction pathway is proposed. This involves applying the halo, utilizing gravity traction, and postponing definitive surgery to a later date, which would allow for optimization of spinal flexibility. Patients undergo a temporary hospital stay followed by discharge to home with the halo device (with the possibility of surgery considered at a later stage). At-Home HGT: Targeting a different subgroup of patients who are medically fit for spinal instrumentation surgery, the at-home HGT program enables patients to receive halo traction treatment at home instead of an extended hospital stay. After a short-term hospitalization, patients spend the remainder of their treatment period at home with the halo device. This allows for a more comfortable and cost-effective alternative to prolonged hospitalization. Currently in the conceptual stage, the program holds significant potential for transforming the treatment landscape for severe spinal deformities, providing safer, more patient-centric alternatives to traditional approaches.

TS-003678 — The IP is a novel approach to the preoperative treatment of severe spinal deformities, particularly in younger patients. Traditionally, halo gravity traction involves the application of a halo device, which requires hospital admission and fixation in the cranium. However, some patients, namely children, may face challenges with anesthesia or have families who prefer noninvasive treatment options. The IP offers a solution by enabling families to apply traction therapy at home without the need for cranial fixation. The device comprises a torso vest with shoulder straps and an optional head support attachment for children without head control. By securing the patient to a frame, gravity traction is applied to the torso, effectively addressing spinal deformities. Its noninvasive nature eliminates the risks associated with anesthesia and cranial fixation, and it offers the flexibility of home-based treatment, reducing the need for hospitalization and improving patient comfort.

TS-003440 — The Continuous Pulse Oximeter (CPO-2) is a conceptual wearable device designed for infants with Bronchopulmonary Dysplasia (BPD) and other patient populations requiring continuous oxygen monitoring. The National Institutes of Health estimates that 10,000-15,000 babies born in the United States develop BPD each year. Inspired by the concept of continuous glucose monitors (CGMs), the CPO-2 aims to offer a wireless, adhesive solution to address the challenges associated with traditional pulse oximeters. The intellectual property involves creating a device that is capable of reading oxygen saturations (spO2) without the need for a separate machine. Unlike current pulse oximeters that are minimally adhesive and connected to a machine via a cord, the CPO-2 would transmit information directly to a smartphone, eliminating the machine and cord, thereby reducing the risk of strangulation and skin breakdown issues. The adhesive component is expected to last for an extended period, potentially 7-10 days or more, reducing the need for frequent probe replacements. Potential applications include adoption by home care companies, which could provide the CPO-2 to families taking infants or children home on oxygen. The device could find utility across various age groups, offering a less cumbersome method for continuous oxygen saturation monitoring. RINCH has filed a provisional application (63/533,946) and the inventor continues to develop and refine this technology.

TS-003439 — The Predictive Model of Sudden Cardiac Death in Anomalous Aortic Origin of Coronary Artery (AAOCA) is a patient-specific computational modeling approach to predict ischemia risk in individuals with anomalous coronaries. Anomalous coronaries are variations or abnormalities in the anatomy of the coronary arteries. These anomalies can differ in presentation and severity, with some increasing the risk of heart problems, such as myocardial ischemia (reduced blood flow to the heart muscle), arrhythmias or sudden cardiac arrest. According to The Cleveland Clinic, up to 1% of the population has an anomalous coronary artery, and most cases are not dangerous. This predictive model utilizes morphological risk factors derived from advanced imaging data to offer a validated method for risk stratification, determining the need for surgery, selecting the type of surgery, assessing the effectiveness of surgery, and evaluating residual ischemia post-surgery. Because there are no effective risk stratification approaches for AAOCA individuals, predicting these life-threatening events is challenging. AAOCA is a significant cause of sudden death in children, and current understanding of the mechanisms leading to ischemia and sudden cardiac death (SCD) is limited. According to the Nora Eccles Harrison Cardiovascular Research and Training Institute, "SCD is one of the most significant causes of natural deaths globally. Annually, just over 300,000 US adult deaths are a result of sudden cardiac death. Roughly half of all cardiovascular disease deaths are from SCD." The proposed model addresses these gaps, potentially shifting the AAOCA field from uncertainty to clinical solutions. RINCH has filed a provisional application (63/502,524) for this technology. The inventors are planning additional refinement of the methodology and a clinical trial to validate the model in a prospective patient population. This technology is jointly owned with Georgia Institute of Technology.